Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Abemaciclib metabolite M18 (LSN3106729) is a potent cyclin-dependent kinase (CDK) inhibitor with antitumor properties. It has been incorporated alongside a cereblon (CRBN) ligand to develop a proteolysis-targeting chimera (PROTAC) that selectively degrades CDK4/6 [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | Abemaciclib metabolite M18 (LSN3106729) is a potent cyclin-dependent kinase (CDK) inhibitor with antitumor properties. It has been incorporated alongside a cereblon (CRBN) ligand to develop a proteolysis-targeting chimera (PROTAC) that selectively degrades CDK4/6 [1] [2]. |
In vitro | Abemaciclib metabolite M18 hydrochloride demonstrates a plasma half-life (T 1/2) of 43.1 hours in healthy subjects [3]. While the primary function of CDK4/6 inhibitors is to prevent retinoblastoma (RB) protein phosphorylation, leading to cell cycle arrest, they also modify cancer cell biology through additional mechanisms [4]. |
In vivo | CDK4/6 inhibitors enhance T-cell persistence and boost immunological memory in mice administered with tumor-specific CD8+ T cells [5]. |
Synonyms | LSN3106729 |
Molecular Weight | 494.54 |
Formula | C25H28F2N8O |
CAS No. | 2704316-81-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Abemaciclib metabolite M18 2704316-81-2 PROTAC Ligands for Target Protein for PROTAC LSN3106729 inhibitor inhibit